Marketing Guides

Archive for March, 2011

Resellerspanel Premieres A New File Manager For Its 5th Anniversary

ResellersPanel a pioneer in private label reseller hosting announces that it has introduced major upgrades to its hosting platform in time for its fifth anniversary celebrations among them a brand new file manager a multicurrency billing solution and a new multistore functionality.

Beside their default store the resellers now have the opportunity to create up to three more entirely independent of each other free reseller web hosting stores configured according to their specific marketing strategies. They can get a unique domain name choose a different website template and activate a separate DNS cluster for each of the stores which will drive brand recognition and significantly increase their reseller anonymity.

The new multicurrency billing solution on the other hand gives the resellers the possibility to offer web hosting and domain registration services in the five most widely used online transaction currencies and directly address the demands of a particular target audience or a specific local market.

The new file manager which has been integrated in the web hosting control panel boasts an entirely new easy to navigate userfriendly interface. Beside the ability to manage multiple files and folders at once the users now have an unprecedented opportunity to edit their files using a WYSIWYG editor and to view the changes they are making directly in a web browser in real time.

The new file manager also gives the clients the opportunity for the first time to upload .zip .rar .tar.gz and .gz archived files and folders which are being automatically unpacked in the selected directory and visually keep track of the process by means of a progress bar. Popup tooltips which contain essential information about a given file or folder and display the actions that can be performed on them selfevident file type icons and image file thumbnails have been introduced as well.

The updates to the multilingual hosting control panel include also the addition of the Chinese language PHP6 support a new domain parking option a WHOIS/ID protection service which allows the registrants to shield their identity against spammers and fraudsters and a new .htaccess file generator which offers IP authentication hotlinking protection SSI activation URL redirection and custom error pages creation.

Nick Blaskov CFO of ResellersPanel said that five years of hard work have passed since ResellersPanel first opened the door to the whole new world of the private brand reseller web hosting services that this special anniversary coincides also with the introduction of several important updates to ResellersPanels platform such as a new file manager which will enable the clients to handle the content of their websites more easily and efficiently and new multistore and multicurrency options which will dramatically expand the marketing reach of the resellers themselves and that ResellersPanel will continue to surprise the hosting community with newer and newer innovations beneficial for it.

About ResellersPanel

ResellersPanel has been at the forefront of reseller hosting for five years now. It is the first and to this date the only company in the web hosting business offering a completely free fullyautomated reseller hosting program which was launched on April 2 2003 and which has so far helped almost 100 000 resellers to set up and establish their own fullfeatured private label web hosting companies. Beside the free program ResellersPanel offers also a cPanel reseller hosting program dedicated semidedicated and virtual private servers domain name registration.

For more information please contact ResellersPanel at:

LiquidNet Ltd.
12 Paveley Court
30 Langstone Way
Mill Hill London NW7 1GR
United Kingdom

1 800 574 0902 US TOLL FREE
44 020 8346 5230 United Kingdom
61280035987 Australia

Email: prresellerspanel.com
URL: http://www.resellerspanel.com

About the writer:  My name is Ross Todoroff. I am the PR manager of ResellersPanel the only company in the web hosting business which offers a completely free fullyautomated reseller hosting program.

Research Report On Global And Chinese Blood Product Industry 2009

The blood product industry is stemmed and developed from the blood transfusion belonging to the conceptual category of biological products. The blood products extracted the plasma proteins and factor concentrates from the blood are the precious human biological products with irreplaceable prevention functions to many diseases. So far there is no qualified manmade substitute.nbsp;

In 2008 the market scale of global blood products were 12 billion USD up by about 10 of 2007. The giants CSL Behring Talecris Biotherapeutics Inc Grifols S.A. Baxter International Inc Octapharma AG and etc occupied the major market shares. The market concentration of the global blood product industry was improved. After the merger of Bayer by Talecris Biotherapeutics Inc CSL Behring merged Talecris Biotherapeutics Inc with 3.1 billion USD.

In 2008 the market scale of Chinese blood products was less than 1 billion USD. Shanghai RAAS Blood Products Co. Ltd Hualan Biological Engineering Inc and Beijing Tiantan Biological Products Co. Ltd were the leaders of Chinese blood product industry. The scales of Chinese domestic blood product enterprises were all very small. The major factors affecting the development of the enterprises were capitals technologies and materials and so on. The competitiveness of Chinese blood product enterprises mainly showed in the plasma volumes in operation production lines and brand construction. The plasma volumes in operation not only represented the scale effect but also reflected the enterprises control abilities of the blood resources; the production lines represented not only the technological levels of the blood product enterprises but also means single product costs undertook by more products. The brand construction represented that the price would not be the only standard to determine the sales volumes because of the special safety requirements of the blood products. The famous enterprises could get comparatively high gross profit rate in the process of competition. In 2008 the gross profits of Chinese blood products were between 20 to 60 percent.

In 2008 the yields of Chinese blood products were decreased compared with last year. However because of the growth in the average sale price of Chinese blood products the total sales revenues were increased compared with last year.

The major reason for the yield decline of Chinese blood products is the bottleneck in the raw materials the policy elements leading to the insufficient collections of the Source Plasma. Out of the consideration for the safety Chinese government lists injection biological products and special medicines as the high risky supervised products blood products and vaccines as the key highly risky products. Since 1st July 2008 Chinese government carried out the inspection period systems to the source plasma before the production of blood products that is to lay aside the collected qualified source plasma for 90 days then make a serological and virology inspection of the donator’s plasma sample if qualified the source plasma could be used into the production of blood products. This measure strengthened the safety of the blood products but leading to the reduction in the plasma collections.nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;

The blood products can not meet the demands in Chinese market. It is estimated that the homophile numbers in China are about 80 to 100 thousand four fifths of which are short of ? factor and only less than 10 of which are received the formal treatments.nbsp;

Out of consideration for the prevention of blood diseases such as AIDS Chinese government limited the imports of blood products abroad from 1986. According to the present situation of the demands of the blood products exceeding the supplies and the pursuit of the blood products the limitations for the blood products will loosen. In May of 2008 Chinese government announced that the import temporary tariff was adjusted from 3 to zone from 1st June 2008 to 3rd December 2008 including antiserum human vaccines culture organism and the similarities of the blood albumin and human vaccines.

The international blood product giants such as CSL Behring and Baxter International Inc. have already distributed in China and developed fast.

With the development of Chinese blood product industry the concentration of Chinese blood product industry is also improved. The competitions among the blood product enterprises are mainly the comprehensive strength competitions such as the researches on the new products the marketing promotions the quality and safety of the products and the control ability of the blood raw materials. Meanwhile the mergers and acquisitions among the enterprises went on all the time. In 2008 Beijing Tiantan Biological Products Co. Ltd had become the largest enterprises of blood products by merging Chengdu Rongsheng Biological Products Co. Ltd

As far as the oversea blood product enterprises are concerned there exists huge market potential in Chinese blood product industry. On the one hand they can obtain rich profits by exporting blood products to China. On the other hand they can set up production bases in China by finding out the merger and acquisition opportunities among Chinese blood product enterprises.

The author wrote this report by the interviews of the patients and enterprises and the profound investigation into Chinese blood product industry.

More following information can be obtained in this report:
Overview of Global Blood Product Industry
Scales of Chinese Blood Product Industry
Development of the Major Products in Chinese Blood Product Industry
Collections of Chinese Blood Product Industry
Policies of Chinese Blood Product Industry
Demands of Chinese Blood Product Industry
Major Enterprises of Chinese Blood Product Industry
Chinese Blood Product Industry
Distributions of International Blood Product Giants in Chinese Market
Favorable and Unfavorable Factors Affecting the Development of Chinese Blood Product Industry
Influences of International Financial Crisis on Chinese Blood Product Industry

To get more details please visit http://www.shcri.com/reportdetail.asp?id=262

About the writer:  Alice is an industry analyst in this field for more than 5 years with depth insight in the recent market trends. Based on the database Interviews and research methods from China Research and Intelligence she analyzes the development and opportunities in this industry clearly.

Research Report On Chinese Anti-Tumor Drug Market 2009

With the deterioration of natural environment and the bad eating habits there is an increasing number in Chinese malignant tumor patients. At present the outbreak rate of Chinese male malignant tumor is 130.3 to 305.4 per one hundred thousand and female of 39.5 to 248.7 per one hundred thousand. In 2008 the new cancer case loads in China exceeded 2.2 million and over 1.6 million deaths. In recent years one in every four to five deaths is died of cancer the leading cause of death. It is predicted that there will be 5.5 million new cancer case loads in 2020 in China and the deaths will reach to four million.

With the growing outbreaks of malignant tumor the cure measures for cancer are advanced too as well as the 5year survival rate of cancer patients. The cure of malignant tumor also brings the development of antitumor drug market. In recent years the scales of Chinese antitumor drug market have been rising. The sales of antitumor drugs in Chinese hospitals are keeping steady growth and making the breakthrough of 5 billion USD in 2007.

China has approved about two hundred kinds of antitumor drugs in the market about 100 kinds for various cancer treatments. Chinese antitumor drugs can be divided into nine categories: Alkylation Agents such as nitrogen mustards ethyleneimines methanesulfonates polyatomic alcohols and SarCNU; Antimetabolite drugs such as pyrimidine antimetabolites purine antimetabolites and antifolates; Antibiotics; Plant antitumor drugs; Hormone antitumor drugs; Platinum metallic antitumor drugs; Others; Aided antitumor Drugs and immunomodulators. The clinical indications of the former sevens center on cancer treatments but the latter two indicate more general adopts in other cures.

The author obtained abundant firsthand information through investigation into the hospitals and manufacturers. This report analyzes Chinese antitumor drug market from the angles of production demands and development trends etc. and is of high value for reference to the understanding of Chinese antitumor drug market and the discovery of market opportunities.

More following information can be obtained in this report:

Analysis on the Outbreaks of Chinese Tumor Diseases

Analysis on the Structure of Chinese Antitumor Drug Market

Scales of Chinese Antitumor Drug Market

Development Trends of Chinese Antitumor Drugs

To get more details please visit Research Report on Chinese AntiTumor Drug Market 2009

About the writer:  Alice is an industry analyst in this field for more than 5 years with depth insight in the recent market trends. Based on the database Interviews and research methods from China Research and Intelligence she analyzes the development and opportunities in this industry clearly.